Bannerbild German Brest Group - Newsroom

The German Breast Group’s newsroom

Our newsroom provides you with the latest information about the German Breast Group. This section of the website also includes photographic material and information about our events. In addition, our Annual Scientific Reports, which provide an overview of our research activities, can be downloaded here.

 
  • 04.07.2019 June 2019: Clinical results and biomarker analysis of the randomised phase II GeparNuevo study

    We are pleased to inform you that the results of the randomised phase II GeparNievo (GBG 89) study that aimed to investigate durvalumab, a PD-L1 inhibitor, in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer (TNBC) has been published in the Annals of Oncology.

  • 03.06.2019 May 2019: Long-term outcomes of the GeparSepto study

    The long-term follow-up data of the phase III GeparSepto (GBG 69) study that aimed to compare weekly nab-paclitaxel with weekly sb-paclitaxel followed by epirubicin plus cyclophosphamide (EC) as neoadjuvant treatment in patients with primary breast cancer has been published in the Journal of Clinical Oncology.

  • 27.05.2019 GBG Research at ASCO Annual Meeting 2019

    Data of several GBG studies conducted together with other collaborative study groups will be presented at the upcoming ASCO 2019, which will take place from May 31 to June 4 in Chicago, IL.

  • 22.05.2019 Mutational landscape and therapy response in GeparSepto trial

    Results of a next-generation sequencing (NGS) analysis conducted in the neoadjuvant GeparSepto study (GBG 69) have been published in the Clinical Cancer Research.

  • 07.05.2019 AURORA: inital results presented

    The initial results of AURORA were announced at the ESMO Breast Cancer Congress in Berlin.

  • 02.05.2019 GBG Research at ESMO Breast Cancer 2019

    Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.

  • 10.04.2019 Results from E-VITA trial conducted with HER2-positive metastatic breast cancer patients

    We are pleased to inform you that the results of the E-VITA study that evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER2-positive metastatic breast cancer has been published in the Anticancer Drugs.

  • 01.03.2019 Evaluation of sCAIX as predictive marker for efficacy of neoadjuvant bevacizumab

    A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.

  • 04.02.2019 ESMO Breast Cancer 2019

    ESMO Breast Cancer 2019

    ESMO Breast Cancer is an annual congress taking place on 2-4 May 2019 in Berlin, Germany.

  • 01.02.2019 Results of the GeparOcto trial

    We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.

  • 18.01.2019 Prof. Loibl among highly cited researchers 2018

    Prof. Dr. Sibylle Loibl, CEO of the GBG Forschungs GmbH and Professor at the Goethe University Frankfurt is featured among these researchers in 2018 for her work in breast cancer research.

  • 17.12.2018 Results of an interim analysis from KATHERINE trial

    We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.

  • 30.11.2018 November 2018: Exploratory analysis on obese breast cancer patients from the PANTHER trial

    Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment has been published in the Annals of Oncology.

  • 29.11.2018 GBG Research at SABCS

    Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.

  • 11.10.2018 BIG newsletter no 9 is out

    We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.

  • 27.09.2018 GBG-Jahrestreffen - Save the Date

    GBG-Jahrestreffen - Save the Date

    Das GBG Jahrestreffen 2019 wird am 14. & 15. März 2019 in Niederrad Frankfurt am Main stattfinden.

  • 27.09.2018 Paper of the month: models for pCR

    Paper of the month: models for pCR

    A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.

  • 11.09.2018 BCC-Breast Cancer Conference 2019 in Vienna

    BCC-Breast Cancer Conference 2019 in Vienna

    The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna is less than seven months away.

  • 31.08.2018 Paper of the month: Endocrine Therapy in HEGR2 neg mBC

    A review that summarized the available data on endocrine therapy for premenopausal women with HER2-negative hormone receptor-positive metastatic breast cancer (MBC) has been published in the Oncologist.

  • 28.08.2018 GBG 79 BrainMet (BMBC): erste Daten publiziert

    Die erste Analyse der BMBC-Registerstudie zur Versorgung von Patientinnen mit Hirnmetastasen wurde im European Journal of Cancer veröffentlicht.

Contact

GBG Forschungs GmbH

Martin-Behaim-Straße 12

63263 Neu-Isenburg

+49610274800

Email us

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd